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Abstract 
Background: Multisystem inflammatory syndrome temporally associated with COVID‑19 (MIS‑C) has been described 
as a novel and often severe presentation of SARS‑CoV‑2 infection in children. We aimed to describe the characteristics 
of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS‑C in comparison with those admit‑
ted with SARS‑CoV‑2 infection with other features such as COVID‑19 pneumonia.
Methods: A multicentric prospective national registry including 47 PICUs was carried out. Data from children admit‑
ted with confirmed SARS‑CoV‑2 infection or fulfilling MIS‑C criteria (with or without SARS‑CoV‑2 PCR confirmation) 
were collected. Clinical, laboratory and therapeutic features between MIS‑C and non‑MIS‑C patients were compared.
Results: Seventy‑four children were recruited. Sixty‑one percent met MIS‑C definition. MIS‑C patients were older 
than non‑MIS‑C patients (p = 0.002): 9.4 years (IQR 5.5–11.8) vs 3.4 years (IQR 0.4–9.4). A higher proportion of them 
had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non‑MIS‑C patients presented more fre‑
quently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS‑C patients showed higher prevalence of fever (95.6% 
vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, 
p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS‑C group had a 
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Background
In January 2020 a novel coronavirus (SARS-CoV-2) 
was described in Wuhan, China. This virus pro-
duces the coronavirus disease 2019 (COVID-19), and 
its rapid spread has led to the declaration of a global 
health emergency and pandemic by the World Health 
Organization [1, 2]. The infection affects adults more 
frequently than children and the clinical manifestations 
of the infection are generally less severe in pediatric 
patients than in adults [3–7].
To date, the scarce literature on pediatric patients 
with SARS-CoV-2 infection shows that it most com-
monly affects short-age children in the form of respira-
tory problems [3, 4, 6–10], although severe respiratory 
symptoms are significantly more frequent in adults 
than in children [11]. Indeed, only a low proportion of 
pediatric patients with SARS-CoV-2 infection require 
intensive care [12, 13], and mortality is lower in chil-
dren than in adults [12].
By the end of April 2020 and the beginning of May, 
several scientific societies reported a new clinical pres-
entation related to SARS-CoV-2 infection [14–17]. This 
syndrome, known as multisystem inflammatory syn-
drome temporally associated with COVID-19 (MIS-C), is 
characterized by fever, abdominal pain, gastrointestinal 
and cutaneous symptoms, and hemodynamic alterations. 
As described in these reports, MIS-C has similar features 
to those of Kawasaki disease (KD), toxic shock syndrome 
(TSS), bacterial sepsis, and macrophage-activation syn-
drome. To date, several publications have reported clus-
ters of patients with different severity in the UK [10, 
18–21], Italy [22], France [23–25], and the USA [26–28]. 
In Spain, 5 cases of children presenting with suspected 
acute abdomen and SARS-CoV-2 infection were initially 
reported in a single-center study [29]. General data of 
patients with SARS-CoV-2 admitted to Spanish PICUs 
have been published with no differentiation of those pre-
senting with MIS-C in a previous report [30].
Although the presence of KD symptoms has been pre-
viously described in patients with infections by other 
coronaviruses [31, 32], the evidence provided on KD in 
pediatric patients with SARS-CoV-2 in the scientific lit-
erature is very limited.
The purpose of this prospective multicenter registry 
carried out in Spain, is to compare the cases of pediatric 
patients with SARS-CoV-2 infection and clinical symp-
toms consistent with MIS-C to those with SARS-CoV-2 
infection not fulfilling MIS-C criteria.
Methods
The Spanish Society of Pediatric Intensive Care pro-
moted the creation of a multicentric prospective registry 
of pediatric patients with SARS-CoV-2 infection admit-
ted to PICUs in Spain. The Registry was approved by the 
Institutional Review Board of the coordinating center 
(Hospital General Universitario Gregorio Marañón). 
The Registry is fed by 47 PICUs, which account for more 
than 90% of the PICUs of the Spanish health system. 
Researchers at each participating PICU were responsi-
ble for identifying those who fulfilled inclusion criteria 
among every admitted patient during the study period. 
Written informed consent was obtained from patients or 
their parents before data collection. Data about patients 
who met inclusion criteria were collected by an elec-
tronic data collection form and entered into the Registry 
by researchers at each site. Data were collected between 
the 1st of March 2020 and the 15th of June 2020. Partial 
data from patients included in the study have been previ-
ously published as case series elsewhere [29, 30].
Inclusion criteria
All patients younger than 18  years admitted to a PICU 
with a diagnosis of SARS-CoV-2 infection were included. 
Patients who met the case definition for MIS-C accord-
ing to the criteria of the Royal College of Paediatrics and 
Child Health (RCPCH) [14] were also included, even 
lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lympho‑
cyte ratio (p < 0.001), C‑reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS‑C group were less 
likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs 
(66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). 
Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 
2.5–8 days) in the MIS‑C group. Three patients died, none of them belonged to the MIS‑C group.
Conclusions: MIS‑C seems to be the most frequent presentation among critically ill children with SARS‑CoV‑2 infec‑
tion. MIS‑C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and 
shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical 
ventilation than non‑MIS‑C patients.
Keywords: SARS‑CoV‑2, Pediatric multisystem inflammatory syndrome temporally associated with COVID‑19, 
Kawasaki disease, Toxic shock syndrome, Children, Critical care, Shock
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lacking a confirmed microbiological diagnosis of SARS-
CoV-2 infection.
A case of MIS-C was defined as persistent fever (for 
longer than 4  days), laboratory data showing inflamma-
tion (neutrophilia, lymphopenia, or elevated C-reactive 
protein) and evidence of organ dysfunction (as described 
in the variables section) with other additional symptoms 
such as cutaneous–mucosal or abdominal involvement. 
Patients with other infections explaining their symptoms 
were excluded. Polymerase chain reaction (PCR) testing 
for SARS-CoV-2 in patients with MIS-C may be positive 
or negative [14].
As cases consistent with MIS-C may have been over-
looked before the definition of this entity was published, 
researchers at every participating PICU were asked to 
perform a retrospective review of all admissions since 
the Registry’s inception. None of the participating PICUs 
identified any patient who met the established criteria 
and had not been previously included in the Registry.
Variables collected
Collected data included the date of admission to and dis-
charge from PICU, demographic variables; any medical 
history of interest; and the main reason for PICU admis-
sion. Other data included were clinical diagnosis within 
the first 24  h of admission, severity scores (PRISM III) 
and multi-organ failure scores (P-SOFA), and other clini-
cal and analytical parameters recorded on admission and 
during the hospital stay. A clinical diagnosis of shock was 
established in the presence of arterial hypotension with 
mean blood pressure values below the 5th percentile of 
the reference values for age, need for vasoactive therapy 
to maintain normal blood pressure, or presence of signs 
of hypoperfusion despite adequate fluid resuscitation. 
Acute cardiac dysfunction was defined as the appearance 
of any of the following echocardiographic alterations: 
global or segmental contractility alterations, ventricular 
dilatation, reduced ejection fraction and/or presence of 
pericardial effusion.
Additional data included the presence or absence of the 
following symptoms: fever, cough, respiratory distress, 
odynophagia, rhinorrhea, diarrhea, nausea, vomiting, 
refusal to eat, headache, irritability, altered level of con-
sciousness, seizures, fatigue, myalgia or abdominal pain.
Additionally, symptoms consistent with hyperinflam-
matory syndromes such as KD and TSS were recorded 
in patients who met the MIS-C case definition. Possible 
symptoms of hyperinflammatory syndromes included 
fever; persistent fever (more than 4  days of duration); 
ocular manifestations such as non-exudative conjunc-
tivitis; oral mucosa lesions; cutaneous manifestations 
(palmar or plantar erythema, edema, swelling, desqua-
mation, erythroderma, or polymorphic erythema in 
the hands and feet); cervical lymphadenopathy; arterial 
hypotension; renal, hematological, or hepatic involve-
ment; presence of Acute Respiratory Distress Syndrome 
(ARDS); neurological involvement, or soft tissue necro-
sis. The presence of ARDS was defined following the 
Pediatric Acute Lung Injury Consensus Conference cri-
teria [33]. For renal involvement, the definition employed 
was an increase in creatinine levels of double the normal 
limits for the age of the patient or twice as baseline cre-
atinine levels. The considered definition of hematologic 
involvement included the presence of coagulopathy 
(aPTT or PT above normal limits) or thrombocytopenia 
(< 100,000 platelets/mcl). Liver involvement was defined 
as an increase in transaminase or bilirubin levels twice 
above baseline or normal values for the age of the patient.
Laboratory data on admission and during hospital stay 
were also collected, including hemoglobin, leukocyte and 
platelet counts, coagulation tests, D-dimer, creatinine, 
urea, liver function markers, LDH, and ions. Inflamma-
tory markers such as C reactive protein (CRP), procal-
citonin (PCT), and IL-6 were recorded. In patients with 
hyperinflammatory symptoms, NT-ProBNP, and serum 
troponin levels were also included. Microbiologically 
confirmed diagnosis of SARS-CoV-2 infection (PCR and 
serology) was also recorded. PCR testing was performed 
on nasopharyngeal swab samples. The microbiological 
tests were carried out according to the established prac-
tice at each participating center.
Besides, antibiotic, antiviral, and immunomodulatory 
therapies administered during PICU stay, respiratory 
and cardiovascular support (administration of vasoac-
tive drugs and/or ECMO) or need for renal replacement 
therapy were obtained.
Statistical analysis
Data were entered into a database that was analyzed 
using the SPPS statistical package (IBM SPSS Statistics, 
Version 25.0. Armonk, NY: IBM Corp). Continuous 
quantitative variables were expressed as median values 
and interquartile ranges as measures of central tendency. 
Comparison of continuous quantitative variables was 
performed using the Wilcoxon rank-sum test. Compari-
son of proportions between subgroups of patients was 
carried out by Chi-squared test and Fisher’s test when 
the first method could not be used due to the small num-
ber of cases. Heatmap and dendrogram were performed 
using Jaccard distance and Jaccard index to describe clus-
ters of co-occurring symptoms. Dendrogram was built 
using Jaccard distance as metric and complete linkage 
as adjustment method. Heatmap and dendrogram were 
drawn using Datagraph for MacOS version 4.5.1 (Visual 
Data Tools Inc. Chapel Hill, NC). When some data were 
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missing, the number of patients whose data were avail-
able for each variable is stated.
Results
Forty-seven PICUs, including 1st, 2nd and 3rd level of 
care, from every region of Spain participated in the Reg-
istry. Between March 1st and June 15th, 2020, a total of 
74 children admitted to the participating PICUs were 
included in the Registry, with ages ranging from 15 days 
to 16.5  years. Forty-five patients (61%) were male, and 
52 (70.3%) had no previous disease. Forty-five patients 
(61%) met the case definition for MIS-C proposed by the 
RCPCH.
SARS-CoV-2 infection was confirmed microbiologi-
cally in 61 of 74 patients (82.4%). Viral RNA was detected 
by PCR in 44 of 74 patients (59.5%). Serologic tests were 
done in 37 patients (50%) being positive in 27 of them 
(73%). The diagnosis was not confirmed microbiologi-
cally in thirteen patients (17.6%) with high suspicion of 
SARS-CoV-2 infection (according to clinical, epidemio-
logical, or radiologic findings) or meeting MIS-C criteria. 
Among patients not presenting with MIS-C, viral RNA 
was detected using PCR in 26 of 29 (89.7%) while in the 
MIS-C group, PCR was positive in 18 out of 45 (40%) 
(p < 0.001). Seventeen of the 27 (63%) patients with nega-
tive PCR testing in the MIS-C group had serological con-
firmation of SARS-CoV-2 infection.
Table  1 compares the baseline characteristics, symp-
toms prior to admission, and clinical diagnoses estab-
lished within the first 24 h of admission of the group of 
patients meeting the case definition for MIS-C vs the 
remainder of patients with SARS-CoV-2 infection admit-
ted to the PICU. The group of patients with MIS-C 
had an older age and higher weight. The proportion of 
patients with a previous medical history of interest was 
lower in the group of patients meeting MIS-C criteria. 
Respiratory symptoms were less frequent in the MIS-C 
patients, whereas the incidence of gastrointestinal symp-
toms and fatigue was higher in this group. The MIS-C 
group presented a higher prevalence of symptoms of 
shock and acute cardiac dysfunction. Clusters of symp-
toms were identified using heatmap and dendrogram 
analysis (Fig. 1). Figure 2 shows the count of new SARS-
CoV-2 positives admitted to the PICU every day separat-
ing patients with MIS-C from the remainder of patients. 
Table 2 displays the incidence of KD and TSS symptoms 
in the 45 patients with MIS-C.
Figure  3 compares the laboratory parameters of 
patients with and without MIS-C. Patients with MIS-C 
exhibited lower levels of lymphocytes and LDH, higher 
levels of CRP and PCT, neutrophils, and a higher lympho-
cyte/neutrophil ratio. Troponin-T was determined in 34 
of the 45 MIS-C patients (75.6%) with a median value of 
55.4 ng/L (IQR 13.3–204.7 ng/L) (normal value < 19 ng/L) 
[34] and NT-ProBNP was determined in 22 patients with 
MIS-C (48.9%) with a median value of 5,532 pg/ml (IQR 
1582–12,783  pg/ml) (normal value < 450  pg/ml) [35]. 
Twenty-two patients in the MIS-C group (48.9%) exhib-
ited echocardiographic signs of ventricular dysfunc-
tion. Coronary arteries abnormalities were reported in 3 
patients in the MIS-C group (6.7%): two patients had a 
homogeneously dilated anterior descendent artery along 
its entire length, and one patient had a dilated left coro-
nary artery with an aneurism in the anterior descendent 
artery.
Support measures and antibiotic, antiviral, and immu-
nomodulatory therapies administered during PICU 
hospitalization are shown in Table  3. Invasive and non-
invasive mechanical ventilation were less used in patients 
with MIS-C, whereas the use of antibiotics and vasoac-
tive and immunomodulatory therapies was more com-
mon in these patients.
Among 18 patients requiring intubation in 11 (61.1%) 
the main reason for intubation was respiratory fail-
ure while in 7 (38.9%) it was due to hemodynamic 
failure. Patients requiring invasive ventilation were 
younger (2.9  years [IQR 0.4–9.5]) than those who did 
not (9.1  years [IQR 4.2–11.9]), p = 0.007. They also had 
higher PRISM-III score (13 points [IQR 8–16]) than non-
ventilated patients (6.5 points [IQR 4–9.3]), p = 0.005, 
and higher p-SOFA scores (6 points [IQR 4–10.5] vs 3 
points [IQR 2–5]), p < 0.001. On the contrary, patients 
requiring ventilation had lower CRP levels (7.1  mg/dl 
[IQR 0.9–21.6]) than non-ventilated patients (20.5 mg/dl 
[IQR 10.3–27.6]), p = 0.017. Among 18 patients requiring 
invasive ventilation, 15 (83.3%) had radiologic alterations 
in the chest x-ray.
Radiologic alterations in the chest-x-ray were present 
in 20 patients (55.6%) with MIS-C features and in 27 
patients (93.1%) without (p = 0.001). The existence of an 
abnormal chest-x-ray was observed in 36 of 44 patients 
(81.8%) with positive PCR for SARS-CoV-2 in the naso-
pharyngeal swab samples and in 16 of 30 patients (53.3%) 
of patients with negative nasopharyngeal swab SARS-
CoV-2 PCR (p = 0.008). Twenty-two patients of 74 
(29.7%) showed normal chest-x-ray at admission. Patients 
with normal chest-x-ray had higher PCT 7.9  mcg/L 
(3.1–55.7) than patients with chest-x-ray alterations 
(1.9 mcg/L [0.3–7.4]), p = 0.006.
Thirty-seven patients required vasoactive drugs, among 
them, 15 (40%) showed conserved cardiac function. 
Noradrenaline and dopamine were used in more patients 
in the MIS-C group (35.5% and 25.8%) compared to the 
non-MIS-C group (7.7% and 4%), p = 0.024 and p = 0.033, 
respectively. Fluid balance per kilogram during the first 
day of admission was 9.2 ml/kg (IQR − 7.1 to 28) in the 
Page 5 of 13García‑Salido et al. Crit Care          (2020) 24:666  
group of patients without MIS-C and 21.8  ml/kg (IQR 
0.2–29.7) p = 0.450.
The administration of antiviral treatments was similar 
in the two groups, except for remdesivir, which was not 
used in patients with MIS-C.
As of June 15, 2020, 65 of the 74 patients (87.8%) 
included in the Registry had been discharged from the 
PICU. The length of stay in patients with MIS-C was 
5  days (2.5–8  days) versus 6.5  days (3.3–10.8  days) in 
the other group (p = 0.523). The patient who required 
VA-ECMO was weaned and discharged to the ward. 
Three patients included in the registry died (4%), all of 
them belonged to the group of patients not presenting 
with MIS-C. All deceased patients previously had seri-
ous illnesses: one of them had a Niemann–Pick disease, 
and the other two had received hematopoietic stem cell 
transplantation due to acute lymphoblastic leukemia 
and to severe immunodeficiency. Deceased patients 
developed severe respiratory distress, one of them died 
while he was on VV-ECMO support due to massive 
pulmonary thromboembolism.
Table 1 Clinical manifestations of SARS-COV-2 in critical pediatric patients
Comparison of patients with MIS‑C and without MIS‑C. Quantitative values are expressed as median values and interquartile range. Qualitative variables are expressed 
as number of cases with respect to the total number of cases in each group and percentages
IQR Interquartile rank, p-SOFA pediatric sequential organ failure, PRISM III Pediatric risk of mortality score, ARDS Acute respiratory distress syndrome. The criteria used 
to define diagnostic variables within the first 24 h of admission are defined in the Materials and Methods section





Gender (male) n/N (%) 46/74 (62.2) 39/45 (66.7) 16/29 (55.2) 0.320
Age (years) Median (IQR) 8.1 (3–11.5) 9.4 (5.5–11.8) 3.4 (0.4–9.4) 0.002
0–5 years n/N (%) 30 (40.5) 12 (26.7) 18 (62.1) 0.003
6–12 years n/N (%) 33 (44.6) 27 (60) 6 (20.7)
 > 13 years n/N (%) 11 (14.9) 6 (13.3) 5 (17.2)
Weight (kg) Median (IQR) 29.5 (15–43.5) 36 (22.5–50) 15.5 (6.5–32.5) < 0.001
Previously healthy n/N (%) 52/74 (70.3) 37/45 (82.2) 15/29 (51.7) 0.005
PRISM III Median (IQR) 7 (4–13.5) 7 (5–14) 7 (3–13) 0.544
p‑SOFA Median (IQR) 4 (2–6) 4 (3–6) 3 (1–5) 0.135
Symptoms prior to PICU admission
Fever n/N (%) 61/73 (83.6) 43/45 (95.6) 18/28 (64.3) < 0.001
Cough n/N (%) 26/73 (35.6) 12/45 (26.7) 14/28 (50) 0.043
Respiratory distress n/N (%) 23/73 (31.5) 6/45 (13.3) 17/28 (60.7) < 0.001
Odynophagia n/N (%) 12/68 (17.6) 9/43 (20.9) 3/25 (12) 0.352
Rhinorrhea n/N (%) 11/71 (15.5) 2/43 (4.7) 9/28 (32.1) 0.002
Diarrhea n/N (%) 33/71 (46.5) 30/45 (66.7) 3/26 (11.5) < 0.001
Nausea n/N (%) 22/53 (41.5) 18/30 (60) 4/23 (17.4) 0.002
Vomits n/N (%) 38/71 (53.5) 32/45 (71.1) 6/26 (23.1) < 0.001
Refusal to eat n/N (%) 48/69 (69.6) 33/43 (76.7) 15/26 (57.7) 0.096
Headache n/N (%) 16/68 (23.5) 13/44 (29.5) 3/24 (12.5) 0.113
Irritability n/N (%) 15/71 (21.8) 9/45 (20) 6/26 (23.1) 0.760
Altered consciousness n/N (%) 5/72 (6.9) 2/45 (4.4) 3/27 (11.1) 0.281
Seizures n/N (%) 1/72 (1.4) 1/45 (2.2) 0/27 (0) 0.435
Fatigue n/N (%) 38/69 (55.1) 29/44 (65.9) 9/25 (36) 0.016
Myalgias n/N (%) 8/67 (11.9) 7/43 (16.3) 1/24 (4.2) 0.143
Diagnoses within the first 24 h of admission
ARDS n/N (%) 11/74 (14.9) 3/45 (6.7) 8/29 (27.6) 0.014
Shock n/N (%) 42/74 (56.8) 38/45 (84.4) 4/29 (13.8) < 0.001
Acute kidney injury n/N (%) 12/74 (16.2) 9/45 (20) 3/29 (10.3) 0.271
Acute cardiac dysfunction n/N (%) 27/74 (36.5) 24/45 (53.3) 3/29 (10.3) 0.001
Acute liver dysfunction n/N (%) 14/74 (18.9) 11/45 (24.4) 3/29 (10.3) 0.131
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Discussion
In general terms, the clinical manifestations of SARS-
CoV-2 infection are less severe in pediatric patients than 
in adults. The study published by Dong et  al. revealed 
that only 6% of the more than 2,000 pediatric patients 
included, developed severe clinical symptoms [7], and 
only a small proportion needed intensive care. Respira-
tory problems are less frequent in children than in adults 
[3].
The occurrence of severe systemic hyperinflammatory 
symptoms probably associated with SARS-CoV-2 infec-
tion in children has raised concerns among scientific 
societies [14–17]. This syndrome, which symptoms 
mimic those of sepsis, KD or TSS, has been described in 
different studies [18–29]. The information available on 
the most severe manifestation of SARS-CoV-2 in chil-
dren is also very limited [12, 36]. Our multicentric Regis-
try identified the differences between PICU patients with 
symptoms of hyperinflammatory syndrome and those 
with SARS-CoV-2 infection without symptoms of hyper-
inflammation. To date large series of pediatric patients 
suffering severe manifestations of SARS-CoV-2 infection 
are lacking, and our study includes an important num-
ber of them. It is the first describing characteristics of 
Fig. 1 Heatmap and dendrogram describing clusters of co‑occurring symptoms. Jaccard index was used to describe co‑occurrence. Jaccard index 
is the ratio of the number of times two symptoms occur together divided by the number of times either of them appears. Jaccard index ranges 
from 0 (symptoms never appear together) to 1 (symptoms always appear together). Red square includes those symptoms clustered in patients 
presenting with MIS‑C features. Blue square includes those symptoms co‑occurring in patients presenting with respiratory disease. ARDS Acute 
respiratory distress syndrome
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SARS-CoV-2 infection comparing the patients present-
ing with multisystem inflammatory symptoms with those 
without.
Whereas the most of COVID-19 patients in the studies 
performed by Shekerdemian et al. and Sachdeva et al. in 
the USA and Canada [12, 36] had respiratory symptoms, 
inflammatory syndromes were more frequent in our 
series. This difference may be explained by the fact that 
Spain is in a more advanced stage of the pandemic, as no 
cases of this type were recorded in our Registry during 
the initial stages. Several studies in different regions have 
shown a delay between the peak of incidence of COVID-
19 cases and the rise in the number of MIS-C cases [10, 
21, 22, 27, 28]. In the same vein, the presence of previous 
comorbidities was higher in the sample of Shekerdemian 
et al. (above 80%), whereas previous comorbidities in our 
sample were only identified in patients without systemic 
inflammatory symptoms, who were prevailingly hospital-
ized during the first weeks of operation of the Registry. 
Many published studies point out that most patients pre-
senting with MIS-C are previously healthy [19–21, 24, 
26–28].
In total, 75% of pediatric patients with MIS-C were 
older than 6 years. This finding contrasts with KD, which 
is more frequent in children less than 5  years old [37]. 
These findings are consistent with those observed in 
the studies published by Whittaker et  al. and Verdoni 
et al. where MIS-C patients are compared with previous 
cohorts of KD patients showing older age [19, 22].
Cluster analysis has identified two big groups of 
patients in our cohort, those presenting with fever, shock, 
acute cardiac dysfunction, and gastrointestinal symptoms 
(the group of patients with MIS-C features), and a second 
Fig. 2 Frequency of new admissions in PICUs participating in the Registry by date of admission. Patients fulfilling MIS‑C criteria and not fulfilling 
MIS‑C criteria are marked with different colors. Black dots represent number of new daily cases of COVID‑19 in Spain according to symptom onset. 
Strict lockdown was imposed in Spain on 15 March, 2020
Table 2 Frequency of  characteristic symptoms of  other 
hyperinflammatory syndromes as  KD and TSS in  patients 
with MIS-C
ARDS Acute respiratory distress syndrome. The criteria used to define the 
different variables are defined in the Materials and Methods section
Symptom Number of patients %
Fever 43/45 95.6
Arterial hypotension for the age 41/45 91.1
Abdominal pain 40/45 90.9
Cutaneous manifestations 31/45 68.9
Prolonged fever (> 4 days) 27/45 60
Hematologic alterations 26/45 68.4
Ocular manifestations 18/45 40
Liver involvement 14/45 31.8
Alterations in the oral mucosa 10/45 27
Renal involvement 8/45 17.8
Neurologic involvement 6/45 13.6
Soft tissue necrosis 2/45 5.4
Lymphadenopathy 2/45 5.4
ARDS 2/45 4.7
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group presenting with respiratory symptoms including 
ARDS that often associates also acute liver and kidney 
dysfunction (the group of patients with a more classical 
presentation of COVID-19).
In patients with MIS-C, gastrointestinal symptoms 
are more frequent than respiratory symptoms, whereas 
patients with SARS-CoV-2 typically show respiratory 
symptoms. This finding contradicts the data reported by 
Shekerdemian et al., who reported a very low incidence 
of gastrointestinal problems (2%) [12]. In our series, 
gastrointestinal symptoms were uncommon in patients 
without MIS-C (4% of these patients have diarrhea), 
whereas more than 60% of patients with inflammatory 
syndromes exhibited gastrointestinal symptoms. This is 
in line with the previously described MIS-C case series, 
in which abdominal symptoms as abdominal pain, diar-
rhea, nausea and vomiting are present in most patients 
[10, 18–24, 26–28].
Fever is the most frequent symptom in patients with 
MIS-C, with 100% of patients developing a fever, whereas 
a third of the patients without MIS-C do not present a 
fever. Almost the totality of patients with MIS-C of our 
series exhibited arterial hypotension. It is worth noting 
that we only analyzed PICU patients. Therefore, there 
may have been patients with milder MIS-C symptoms 
who did not develop hemodynamic alterations and did 
not require intensive care as described in studies that 
include patients not requiring intensive care [19, 20, 22, 
23, 27, 28].
As mentioned above, the clinical-laboratory manifesta-
tions of MIS-C mimic those of KD and TSS, and a high 
proportion of patients may meet the diagnostic criteria 
for both diseases [37, 38]. However, some of the typical 
symptoms of these diseases were very uncommon in our 
series, especially the typical cervical adenopathy of KD or 
the oral mucosa and lips lesions (only present in 1 out of 
4 patients of our series) [37]. Some studies have described 
how the presence of cutaneous manifestations in children 
with MIS-C might vary according the age, being less fre-
quent in older patients [27, 28].
Fig. 3 Laboratory findings of patients fulfilling and not fulfilling MIS‑C criteria
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Concerning the laboratory parameters, the MIS-C 
patients presented severe inflammation, with very ele-
vated levels of acute-phase reactants (CRP and PCT), 
exceeding those of SARS-CoV-2 patients without MIS-
C. Although absolute leukocyte counts were not very 
elevated and were similar in the two groups, patients 
with MIS-C exhibited severe lymphopenia, with a high 
neutrophils/lymphocyte ratio and a low platelet count. 
Special attention needs to be paid to the fact that LDH 
was lower in patients with MIS-C as compared to those 
without MIS-C, since elevated LDH levels may be associ-
ated with hemolysis or myocardial damage. The clinical 
interpretation of this finding is challenging. The analyti-
cal findings in our series were similar to those previously 
reported, i.e., lymphopenia without significant leukocy-
tosis, thrombocytopenia, and high CRP and PCT [18–22, 
27, 28].
Hyperinflammatory state has been previously reported 
in adults presenting with COVID-19. This hyperinflam-
matory state has been related to disease severity and the 
need for mechanical ventilation and has been described 
in the context of classic COVID-19 syndrome present-
ing with bilateral pneumonia [39, 40]. In our study, 
contrary to the studies in adults, patients presenting 
with hyperinflammatory features such as elevated CRP, 
showed lower prevalence of chest x-ray abnormalities 
and lesser need of mechanical ventilation. Our study 
points out differences regarding hyperinflammatory 
states related to SARS-CoV-2 infection in children as 
compared to those described in adults. In adults, hyper-
inflammation is more frequent in the context of COVID-
19 bilateral pneumonia and in children in patients with 
mild or absent respiratory symptoms presenting gastro-
intestinal symptoms and shock fulfilling MIS-C criteria.
Several authors have proposed a mechanism of 
immune dysregulation underlying MIS-C cases. In chil-
dren, increased antibodies against receptor binding 
domain of SARS-CoV-2 have been described in patients 
with MIS-C compared with patients with COVID-19 
without hyperinflammatory features [41]. Activation of 
neutrophils and monocytes has been also described in 
the acute phase of pediatric patients with MIS-C with 
normalization in the resolution and convalescent phases 
of the disease [42]. In adults with severe COVID-19, 
hyperinflammation and abnormal activation of different 
cell lineages have also been described widely [43]. How-
ever, it remains unclear why in children, SARS-CoV-2 
related hyperinflammatory states seems to affect more 
Table 3 Support measures and pharmacological treatments administered to patients admitted for SARS-COV-2
Comparison of patients with MIS‑C and without MIS‑C
HFO high‑flow rate oxygen, NIV noninvasive ventilation, MV invasive mechanical ventilation, V-V-ECMO veno‑venous extracorporeal membrane oxygenation, V-A 
ECMO veno‑arterial extracorporeal membrane oxygenation, NOi Inhaled nitric oxygen, CRRT continuous renal replacement therapy





Support measures. n/N (%)
Oxygen therapy 56/74 (79.7) 36/45 (80) 20/29 (69) 0.215
HFO 26/74 (35.1) 14/45 (31.1) 12/29 (41.4) 0.379
NIV 9/74 (12.2) 2/45 (4.4) 7/29 (24.1) 0.026
MV 18/74 (24.3) 6/45 (13.3) 12/29 (41.4) 0.005
Neuromuscular blockade 12/74 (16.2) 3/45 (6.7) 9/29 (31) 0.009
Ventilation in prone position 9/74 (12.2) 1/45 (2.2) 8/29 (27.6) 0.002
V‑V‑ECMO 1/74 (1.4) 0/45 (0) 1/29 (3.4) 0.394
A‑V‑ECMO 1/74 (1.4) 1/45 (2.2) 0/29 (0) 1
NOi 3/74 (4.1) 0/45 (0) 3/29 (10.3) 0.057
CRRT 0/74 (0) 0/45 (0) 0/29 (0) ‑
Transfusion of hemoderivatives 14/74 (18.9) 5/45 (11.1) 9/29 (31) 0.034
Vasoactive drugs 37/74 (50) 30/45 (66.7) 7/29 (24.1) < 0.001
Pharmacological therapies n/N (%)
Antibiotic 65/74 (87,8) 42/45 (93.3) 23/29 (79.3) 0.020
Lopinavir–ritonavir 30/74 (40.5) 18/45 (40) 12/29 (41.4) 0.857
Remdesivir 5/74 (6.8) 0/45 (0) 5/29 (17.2) 0.006
Hydroxychloroquine 43/74 (58.1) 25/45 (55.6) 18/29 (62.1) 0.550
Corticosteroids 49/74 (66.2) 36/45 (80) 13/29 (44.8) 0.003
Immunoglobulins 25/74 (33.8) 23/45 (51.1) 2/29 (6.9) < 0.001
Tocilizumab 17/74 (23) 11/45 (24.4) 6/29 (20.7) 0.871
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frequently cardiovascular and digestive organs instead of 
the lungs as seen in adults.
With regard to the treatments administered, most 
MIS-C patients admitted to the PICU required vasoac-
tive therapy, whereas this therapy was less frequent in 
patients without this MIS-C. There was a high propor-
tion of MIS-C patients requiring vasoactive drugs with 
conserved cardiac function and use of noradrenaline was 
also higher in this group. These facts might point out an 
important element of vasoplegia in MIS-C patients.
In contrast with the use of vasoactive drugs, the need 
of mechanical ventilation was higher amongst those 
patients without MIS-C. In overall terms, the use of 
mechanical ventilation nearly reached 30%, which is 
similar to the percentage reported in studies about 
PICU admissions including children with SARS-CoV-2 
related diseases [12, 36]. In our population of patients 
with MIS-C, the use of mechanical ventilation was infre-
quent (below 15%) as described by Dufort et al. in New 
York State [28], and lower to the rates described in stud-
ies from other regions as U.S.A., U.K. and France where 
more than 30% of patients with MIS-C needed mechani-
cal ventilation.
As to pharmacological treatments, most patients with 
MIS-C included in the Registry received antibiotic ther-
apy. The use of immunomodulatory and corticosteroid 
treatments was also higher in the group of patients with 
MIS-C. No differences were observed in the use of antivi-
ral treatments, although remdesivir was not administered 
to any of the patients with MIS-C. Remdesivir availability 
was limited in Spain during this phase of the pandemic. 
The distribution of remdesivir was subject to request and 
authorization by the ministry of health and administra-
tion in children was considered only in the context of a 
clinical trial. Remdesivir administration was requested 
in several patients in the MIS-C group but delay related 
to approval and favorable course in most MIS-C patients 
probably determined the difference in its use between 
groups. In view of the scant evidence available on the 
effectiveness of antiviral therapies in the treatment of 
SARS-CoV-2, further studies should be conducted to 
assess the efficacy of the immunomodulators used to 
treat similar symptoms to those described above (such as 
steroids and immunoglobulins) to attenuate the inflam-
matory mechanisms involved in the disease [44]. Treat-
ments used in patients with MIS-C are similar to those 
described in studies from other regions [21, 27, 28].
The relationship observed between time and the 
occurrence of MIS-C cases is worthy of note. All MIS-C 
patients were admitted to the PICU at least 15  days 
after the lockdown was imposed in Spain on March 15, 
2020. In the stage where the first patients with MIS-C 
were recorded, in early April, the number of new cases 
was already decreasing. The simultaneous occurrence 
of similar symptoms to those described in our series in 
other European countries [18–24] leads us to foresee 
an increase in the incidence of this syndrome in more 
advanced stages of the epidemic in countries where the 
coronavirus spike occurred some weeks later than in 
Europe. This added to the fact that PCR was negative 
in more than half of MIS-C patients but serology was 
positive for SARS-CoV-2 in a high proportion of them 
suggests that MIS-C may be caused by an underlying 
deregulation of the immune system, with the viral infec-
tion triggering a hyperinflammatory response rather than 
being a direct expression of SARS-CoV-2 infection [22].
As to prognosis, the course of MIS-C patients included 
in our registry was generally favorable, without any mor-
tality. Most patients were discharged to the ward in a few 
days. Other studies describe similar findings with low 
mortality in patients with MIS-C (below 3% in all series) 
[19, 21, 23, 24, 27, 28].
Limitations
This study has some limitations. First, it is a multicen-
tric study that includes most—but not all—PICUs in 
Spain. Therefore, some patients with similar symptoms 
could have not been included in the study. We consider 
that PICUs not participating in the registry do not rep-
resent a specific region or subset of PICUS that might 
prevent generalizing our results to all Spanish PICUs. 
Secondly, the new syndrome observed led us to retro-
spectively review the potential cases that may have been 
overlooked. Although the participating PICUs reviewed 
their records, some patients may have not been included. 
Although it is a prospective Registry, some clinical or lab-
oratory variables were missing. Beside this, each hospital 
had their own microbiological tests and thus differences 
on diagnostic precision regarding SARS-CoV-2 infec-
tion might be present. As only patients admitted to PICU 
were included in the registry, we consider that probably 
our study does not include the whole spectrum of MIS-C 
and some patients might develop milder manifestations. 
Finally, the long-term course of patients could not be 
analyzed, given the short period of time elapsed from 
the onset of the clinical symptoms and analysis. In this 
sense, given that KD is one of the most frequent causes 
of heart disease acquired in childhood, it would be very 
interesting to describe the incidence of coronary lesions 
in patients with MIS-C.
Conclusions
Although SARS-CoV-2 infection is less severe in chil-
dren than in adults, some pediatric patients may present 
severe symptoms requiring intensive care. In Spain, most 
pediatric patients requiring intensive care presented 
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with hyperinflammatory syndrome instead of classic 
COVID-19 disease with severe respiratory involvement. 
This syndrome is characterized by fever, hypotension, 
gastrointestinal symptoms and cutaneous manifestations 
with elevation of inflammatory markers together with 
significant lymphopenia, requiring vasoactive therapy. 
The course of this syndrome is generally favorable. The 
number of cases of MIS-C was higher after the spike in 
coronavirus cases in Spain. This, and the fact that it is 
frequent that MIS-C patients have negative SARS-CoV-2 
PCR tests supports a causal link between SARS-CoV-2 
and MIS-C in which children immune response dysreg-
ulation might be involved. Larger, international, multi-
centric studies are needed to characterize this syndrome 
more accurately and establish the optimal treatment. 
Health policies regarding pediatric intensive care units 
preparedness for SARS-CoV-2 pandemic should take into 
account that a high proportion of patients will present 
with MIS-C. Therefore, specific management protocols 
should be elaborated, and resource acquisition and distri-
bution should consider the previously described patients 
characteristics and therapeutic needs.
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